Skip Navigation


Europace Advance Access originally published online on March 26, 2008
Europace 2008 10(5):536-539; doi:10.1093/europace/eun070
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
10/5/536    most recent
eun070v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lim, H. S.
Right arrow Articles by Tse, H.-F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, H. S.
Right arrow Articles by Tse, H.-F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

ICDs

Implantable cardioverter defibrillator following acute myocardial infarction: the ‘48-hour’ and ‘40-day’ rule

Hoong Sern Lim1,*, Gregory Y.H. Lip1 and Hung-Fat Tse2

1 University Department of Medicine, City Hospital, Birmingham B18 7QH, UK; 2 Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong, China

Until recently, randomized studies of implantable cardioverter defibrillator (ICD) have only included patients with a remote history of myocardial infarction (MI). Two studies evaluated the use of ICDs early following MI, the DINAMIT and BEST+ICD studies, but failed to demonstrate significant reduction in mortality. Current guidelines therefore recommend deferring ICD implantation for at least 40 days following MI. This article highlights the limitations of these two studies and reviews the application of the ‘40-day’ rule to patients with acute MI.

Key Words: Implantable cardioverter defibrillator, Acute myocardial infarction

* Corresponding author. Tel: +44 121 507 5080; fax: +44 121 554 4083. E-mail address: hsern{at}doctors.net.uk

Manuscript submitted 28 January 2008. Accepted after revision 28 February 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.